Restenosis
Return to Library
Research from B.Y. Cha and colleagues provide new insights into life sciences
2009 JUL 27 - (NewsRx.com) -- "Platelet-derived growth factor (PDGF)-BB is one of the most potent factors in the development and progression of various vascular disorders such as restenosis and atherosclerosis. Chrysoeriol is a flavonoid with antioxidant and anti-inflammatory activities," scientists in Matsumoto, Japan report. "In this study, we investigated the effect of chrysoeriol on the proliferation of human aortic smooth muscle cells (HASMC). Chrysoeriol significantly inhibited PDGF (20 ng/mL)-induced migration and [H-3]-thymidine incorporation into DNA at concentrations of 5 and 10 mc M Without any cytotoxicity. Chrysoeriol also blocked PDGF-stimulated dissociation of actin filament and inhibited PDGF beta-receptor (R beta) phosphorylation in a concentration-dependent manner. As a result, the down-stream signal transduction pathways of PDGF-R beta including EPK1/2, p38, and Akt phosphorylation, were also inhibited by chrysoeriol in the same pattern," wrote B.Y. Cha and colleagues. The researchers concluded: "These findings Suggest that in addition to its antioxidant and anti-inflammatory activities, chrysoeriol may be used for the prevention and treatment of vascular diseases and during restenosis after coronary angioplasty.." Cha and colleagues published their study in the Journal of Pharmacological Sciences (An Inhibitory Effect of Chrysoeriol on Platelet-Derived Growth Factor (PDGF)-Induced Proliferation and PDGF Receptor Signaling in Human Aortic Smooth Muscle Cells. Journal of Pharmacological Sciences, 2009;110(1):105-110). For additional information, contact J.T. Woo, Chubu University, Research Institute Biology Functioning, 1200 Matsumoto, Aichi 4878501, Japan. The publisher's contact information for the Journal of Pharmacological Sciences is: Japanese Pharmacological Society, Editorial Off, Kantohya Bldg Gokomachi-Ebisugawa Nakagyo-Ku, Kyoto, 604, Japan. Keywords: Japan, Matsumoto, Life Sciences, Restenosis, Surgical Technology, Surgery, Heart Disease, Coronary Disease, Atherosclerosis, Therapy, Treatment, Antiinflammatory, DNA, Pharmacological Sciences, Hematology, Pharmaceuticals. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
